Glaucoma Therapeutics Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018–2026 © Coherent market Insights. All Rights Reserved REPORT DESCRIPTION Glaucoma Therapeutics Market Overview Glaucoma refers to the group of conditions characterized by optic nerve damage, visual field loss, and secondary to retinal ganglion cell damage, which may lead to death. According to the International Agency for the Prevention of Blindness: 2017, glaucoma is second leading cause of blindness and leading cause of irreversible blindness worldwide. The most common types of glaucoma are Primary Open Angle Glaucoma (POAG) and Primary Angle Closure Glaucoma (PACG). Moreover, PACG is most common in South-East Asian population while POAG is most common in white Caucasians and individuals of African origin. PACG is associated with a high risk of blindness as compared to POAG. A sample of this report is available upon request: https://www.coherentmarketinsights.com/insight/request-sample/1731 Increasing number of patients with glaucoma and increasing incidences of blindness are expected to be the major driving factor for growth of the global glaucoma therapeutics market. According to the International Agency for the Prevention of Blindness, 2010 data findings, it is estimated that by 2020, around 80 million people will suffer from glaucoma, with an increase of about 20 million form 2010. Furthermore, in 2010, over 8 million people were bilaterally blind due to glaucoma, which is expected to increase to over 11 million by 2020. The significant risk of developing glaucoma increases with geriatric population, increased intraocular pressure, positive family history for glaucoma, and ethnicity. According to the American Academy of Ophthalmology (AAO), 2016: the global prevalence of glaucoma is estimated to rise to 76 million in 2020 and 111.8 million in 2040. © Coherent market Insights. All Rights Reserved REPORT DESCRIPTION Glaucoma may occur among the people with or without diabetes. Moreover, people with diabetic retinopathy have an increased risk of glaucoma. The condition is associated with abnormal blood vessel growth, which can result in retinopathy and leads to blockage of natural drainage of the eye. Rapidly increasing geriatric population is one of the important factors for increasing prevalence of glaucoma, which in turn is projected to drive growth of the glaucoma therapeutics market in near future. For instance, according to the International Diabetes Foundation (IDF) 2017 statistics, the number of people with diabetes aged between 20 to 79 years are increasing worldwide. Among which, Africa (156%) is accounted to register the highest diabetic population, followed by Middle East (110%), South East Asia (84%), Latin and Central America(62%), North America (35%), Europe (16%), and Western Pacific (15%). On the basis of region, glaucoma therapeutics market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in glaucoma therapeutics market, followed by Asia Pacific. Increasing prevalence of diabetes, increasing ocular disorders, and increasing number of blind and visually impaired people in turn opting for glaucoma treatment are expected to drive growth of the glaucoma therapeutic market in these region. Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/glaucoma-therapeutics-market-1675 © Coherent market Insights. All Rights Reserved REPORT DESCRIPTION For instance, According to National Federation of the Blind, 2014, an estimated 10 million people in the U.S. are blind or visually impaired. It is estimated that around 1.3 million people are legally blind in the U.S. and the number is projected to increase to 75,000 people annually in the U.S. Asia Pacific is expected to gain a significant traction over the forecast period, owing to the government initiatives and awareness programs to eliminate the blindness, which in turn is propelling demand for glaucoma therapies in this region. For instance, in 2014, HelpAge India— a nonprofit organization—launched a special campaign to address the issue of blindness for underprivileged elderly populations of India. Get Exclusive Discount on this CMI Report: https://www.coherentmarketinsights.com/insight/request-discount/1675 Some of the key players operating in the glaucoma therapeutics market include Valeant Pharmaceuticals International, Inc., Allergan Inc., Merck KGaA, Fera Pharmaceuticals, LLC, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Aristo Pharmaceuticals Pvt. Ltd., Santen Pharmaceutical Co., Ltd., Aerie Pharmaceuticals, and Novartis AG. Key players in the market are focusing on organic growth strategies in order to gain maximum market share and retain leading position in the market. For instance, in December 2017, Aerie Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for Rhopressa (netarsudil ophthalmic solution) 0.02%, indicated for lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. © Coherent market Insights. All Rights Reserved ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES INDUSTRY ANALYSIS CUSTOMIZED RESEARCH SYNDICATED RESEARCH MARKET INTELLIGENCE SERVICES CONSULT STUDIES COUNTRY SPECIFIC STUDIES © Coherent market Insights. All Rights Reserved ABOUT CMI SECTOR COVERAGE BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL DEVICES MEDICAL IMAGING PHARMACEUTICAL OUR CLIENTS Global Leading Equipment and System Manufacturers Marketing Consultancies and the Advertising Industry Component Providers and System Integrators Private and Government organization Distributors, Retailors and Value Added Resellers Outsourcing Companies Healthcare IT Solutions Developers Universities and Business Schools. © Coherent market Insights. All Rights Reserved KEY STATS RESEARCH SOLUTIONS 100+ FEASIBILITY STUDIES Insights Published Per Year GLOBAL REPORTS 150+ Consulting Projects Till Date COUNTRY ANALYSIS CONSULT PROJECTS 125+ Clients Worldwide Per Year 110+ SURVEY RESEARCH EXCEL FORECAST DATABASE CUSTOMIZED SOLUTIONS COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: [email protected] For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights [email protected] +1-206-701-6702 © Coherent market Insights. All Rights Reserved
Glaucoma refers to the group of conditions characterized by optic nerve damage, visual field loss, and secondary to retinal ganglion cell damage, which may lead to death. According to the International Agency for the Prevention of Blindness: 2017, glaucoma is second leading cause of blindness and leading cause of irreversible blindness worldwide. The most common types of glaucoma are Primary Open Angle Glaucoma (POAG) and Primary Angle Closure Glaucoma (PACG). Moreover, PACG is most common in South-East Asian population while POAG is most common in white Caucasians and individuals of African origin. PACG is associated with a high risk of blindness as compared to POAG. To get holistic SAMPLE of the report including table of contents: https://www.coherentmarketinsights.com/ongoing-insight/toc/1675
© Copyright 2024 Paperzz